Vertex Pharmaceuticals

CompanyUnited StatesFounded 1989

Vertex Pharmaceuticals develops one asset, in phase 3 (povetacicept in immunoglobulin a nephropathy). Mostly protein or enzyme acting on inflammation, TNFSF13 and TNFSF13B; based in the United States, founded in 1989.

1
Asset
Furthest: Phase 3; 6
Trials: 1
Signal

Pipeline

1

povetacicept
Dual BAFF and APRIL antagonist fusion protein
Phase 3, Protein or enzyme, Inflammation, TNFSF13, immunoglobulin a nephropathy

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Trials7
Signals3
Similar companies6

Updated 8 Oct 2026 · 10 sources